China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 7.64 billion. The enterprise value is 8.83 billion.
| Market Cap | 7.64B |
| Enterprise Value | 8.83B |
Important Dates
The next estimated earnings date is Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | May 27, 2025 |
Share Statistics
Sirio Pharma has 305.96 million shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 305.96M |
| Shares Outstanding | 305.96M |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | -0.15% |
| Owned by Insiders (%) | 20.73% |
| Owned by Institutions (%) | 11.93% |
| Float | 111.11M |
Valuation Ratios
The trailing PE ratio is 22.04 and the forward PE ratio is 22.75.
| PE Ratio | 22.04 |
| Forward PE | 22.75 |
| PS Ratio | 1.71 |
| PB Ratio | 2.78 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | 37.02 |
| P/OCF Ratio | 10.98 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.14, with an EV/FCF ratio of 42.83.
| EV / Earnings | 25.56 |
| EV / Sales | 1.98 |
| EV / EBITDA | 14.14 |
| EV / EBIT | 20.30 |
| EV / FCF | 42.83 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.89 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 2.73 |
| Debt / FCF | 8.27 |
| Interest Coverage | 4.47 |
Financial Efficiency
Return on equity (ROE) is 10.94% and return on invested capital (ROIC) is 10.04%.
| Return on Equity (ROE) | 10.94% |
| Return on Assets (ROA) | 4.87% |
| Return on Invested Capital (ROIC) | 10.04% |
| Return on Capital Employed (ROCE) | 9.09% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | 124,470 |
| Employee Count | 2,776 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 5.56 |
Taxes
In the past 12 months, Sirio Pharma has paid 38.53 million in taxes.
| Income Tax | 38.53M |
| Effective Tax Rate | 11.69% |
Stock Price Statistics
The stock price has increased by +30.94% in the last 52 weeks. The beta is 0.46, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +30.94% |
| 50-Day Moving Average | 24.30 |
| 200-Day Moving Average | 23.46 |
| Relative Strength Index (RSI) | 51.97 |
| Average Volume (20 Days) | 3,675,267 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.45 billion and earned 345.53 million in profits. Earnings per share was 1.13.
| Revenue | 4.45B |
| Gross Profit | 1.43B |
| Operating Income | 435.24M |
| Pretax Income | 329.66M |
| Net Income | 345.53M |
| EBITDA | 589.63M |
| EBIT | 435.24M |
| Earnings Per Share (EPS) | 1.13 |
Balance Sheet
The company has 605.41 million in cash and 1.71 billion in debt, with a net cash position of -1.10 billion or -3.60 per share.
| Cash & Cash Equivalents | 605.41M |
| Total Debt | 1.71B |
| Net Cash | -1.10B |
| Net Cash Per Share | -3.60 |
| Equity (Book Value) | 2.75B |
| Book Value Per Share | 8.69 |
| Working Capital | 972.44M |
Cash Flow
In the last 12 months, operating cash flow was 695.53 million and capital expenditures -489.27 million, giving a free cash flow of 206.27 million.
| Operating Cash Flow | 695.53M |
| Capital Expenditures | -489.27M |
| Free Cash Flow | 206.27M |
| FCF Per Share | 0.67 |
Margins
Gross margin is 32.11%, with operating and profit margins of 9.77% and 7.76%.
| Gross Margin | 32.11% |
| Operating Margin | 9.77% |
| Pretax Margin | 7.40% |
| Profit Margin | 7.76% |
| EBITDA Margin | 13.24% |
| EBIT Margin | 9.77% |
| FCF Margin | 4.63% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.00%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 2.00% |
| Dividend Growth (YoY) | -23.18% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 49.89% |
| Buyback Yield | -0.24% |
| Shareholder Yield | 1.74% |
| Earnings Yield | 4.52% |
| FCF Yield | 2.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Sirio Pharma has an Altman Z-Score of 2.9 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.9 |
| Piotroski F-Score | 5 |